Cargando…

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

INTRODUCTION: Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative B cell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as “cure”. METHODS: This study used a Delphi panel approach to exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bassan, Renato, Hoelzer, Dieter, Thomas, Xavier, Montesinos, Pau, Pavlu, Jiri, McKendrick, Jan, Kudlac, Amber, Barlev, Arie, Barber, Beth, Cong, Ze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824362/ https://www.ncbi.nlm.nih.gov/pubmed/30847777 http://dx.doi.org/10.1007/s12325-019-00910-z

Ejemplares similares

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
por: Barlev, Arie, et al.
Publicado: (2016)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom
por: Aristides, Mike, et al.
Publicado: (2015)

Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians
por: Saltman, Deborah, et al.
Publicado: (2015)

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
por: Boluda, Blanca, et al.
Publicado: (2018)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
por: Liam, Christopher Chin Keong, et al.
Publicado: (2022)

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
por: Cella, David, et al.
Publicado: (2018)

Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan
por: Imamura, T, et al.
Publicado: (2016)

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)

Changing of IKZF1 genotype during Philadelphia-negative precursor-B acute lymphoblastic leukemia progression: a short clinical report
por: Vshyukova, Volha, et al.
Publicado: (2016)

A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
por: Li, Lan-Zhu, et al.
Publicado: (2020)

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
por: Rambaldi, Alessandro, et al.
Publicado: (2019)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kawano, Noriaki, et al.
Publicado: (2020)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
por: Saleh, Khalil, et al.
Publicado: (2022)

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
por: Soverini, Simona, et al.
Publicado: (2019)

Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
por: Ay, Yilmaz, et al.
Publicado: (2010)

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014)

Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
por: Shah, Gaurav, et al.
Publicado: (2019)

The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia
por: Shiraz, Parveen, et al.
Publicado: (2020)

Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2021)

Outcomes of Philadelphia Positive Acute Lymphoblastic Leukemia in Adolescent and Young Adults
por: Ahmed, Umair, et al.
Publicado: (2022)

Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan
por: Hsu, Yin-Chen, et al.
Publicado: (2021)

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
por: van der Sligte, Naomi E, et al.
Publicado: (2015)

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
por: Lussana, Federico, et al.
Publicado: (2020)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison
por: Quinn, Casey, et al.
Publicado: (2016)

Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper
por: Soverini, Simona, et al.
Publicado: (2020)

Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia
por: Park, Han-Seung
Publicado: (2020)

How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia
por: Frisch, Avraham, et al.
Publicado: (2019)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter
por: Ribera, Josep-Maria
Publicado: (2021)

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
por: Ribera, Josep‐Maria, et al.
Publicado: (2020)

Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
por: Chiaretti, Sabina, et al.
Publicado: (2014)

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study
por: Ascierto, Paolo A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_303ehavoe6e5qqtu9u7iuf6o2j